Compare Gaming and Leisure Properties Inc. Common Stock (GLPI) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gaming and Leisure Properties Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.15B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Gaming and Leisure Properties Inc. Common Stock and Vaxcyte Inc. Common Stock are close in size by market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.56% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GLPI | PCVX | |
|---|---|---|
Market Cap | $11.15B | $10.51B |
Volume | 1,865,490 | 2,644,694 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $73.82 |
52-Week Low | $37.59 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $19.21B | $9.14B |
Dividend Yield | 8.56% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gaming and Leisure Properties Inc. Common Stock
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
